INTRODUCTION

Gastroesophageal varices are present in approximately 50% of patients with cirrhosis. Their presence correlates with the severity of liver disease; while only 40% of Child A patients have varices, they are present in 85% of Child C patients (1, 2). Variceal hemorrhage occurs at a yearly rate of 5-15%, and about 20% of cirrhotic patients with acute variceal bleeding die within 6 weeks (3-5). Although variceal bleeding ceases spontaneously in 40-50% of patients, the incidence of early rebleeding ranges between 30% and 40% within the first 6 weeks, and about 40% of all rebleeding episodes occur in within the first 5 days (4, 6).

Gastric varices (GV) bleed less frequently than esophageal varices and are the bleeding source in approximately 10-30% of patients suffering from variceal hemorrhage (7). However, gastric variceal bleeding tends to be more severe with higher mortality. Additionally, a high proportion of patients, from 35% to 90%, rebleed after spontaneous hemostasis.

Although GV have long been recognized, our understanding of their natural history has lagged far behind that of esophageal varices. Recently, new endoscopic treatment options and interventional radiological procedures have broadened the therapeutic armamentarium for GV. This review provides an overview of the classification and pathophysiology of GV, which have direct consequences for management; an introduction to current endoscopic and interventional radiological management options for GV; and details of a practical approach to endoscopic variceal obturation using N-butyl-2-cyanoacrylate.

INDEX TERMS: Endoscopic; Fundal; Gastric; Varix

Classification and Pathophysiology of GV

GV are heterogeneous entities in terms of the direction of blood flow, as well as their location and shape. GV are categorized into 4 types based on the relationship with esophageal varices, as well as by their location in the stomach: gastroesophageal varix (GOV) type 1, GOV type 2,
isolated gastric varix (IGV) type 1, and IGV type 2 (Fig. 1) (9). GOV type 1 is the most common type, accounting for 74% of all GV. However, the incidence of bleeding is highest with IGV type 1 followed by GOV type 2. These two types of varices are classified as fundal varices and are the most challenging varices to treat.

The wall stress of the varix is ultimately what determines whether it ruptures or not. Wall stress is defined by the equation $\sigma = \frac{p}{w}$, in which $\sigma$ is the wall stress, $p$ is the transmural pressure (the portal pressure), $r$ is the radius, and $w$ is the wall width. Clearly, if an increase in the transmural pressure occurs, this can lead to both an enlargement of the varix ($r$) and a decrease in varix wall thickness ($w$) (9, 10). Thus, small increments in portal pressure can lead to an exponential increase in the wall stress ($\sigma$), precipitating rupture. This explains in part why GV, which are usually larger than esophageal varices, can rupture, despite possessing thicker walls and lower portal pressures than esophageal varices (11).

Overall, the most important predictor of hemorrhage is the size of varices, with the highest risk of first hemorrhage (15% per year) occurring in patients with large varices (12). Other predictors of hemorrhage are decompensated cirrhosis (Child B or C) and the endoscopic presence of red wale marks (12).

Management of Bleeding GV

Diagnostic endoscopy should be performed for acutely bleeding patients as soon as possible to determine the site of bleeding. Even patients with portal hypertension and documented varices can bleed from other sources than varices (13, 14). When a varix is identified and no other source of bleeding is evident, the varix should be regarded as the source of bleeding and should be treated to prevent rebleeding.

The optimal management of bleeding GV remains controversial due to a lack of large, randomized, controlled trials. Although endoscopic variceal band ligation is the undisputed gold standard therapy for bleeding esophageal varices, this approach has been less successful for the treatment of bleeding GV (15). Treatment options for GV include radiological intervention; transjugular intrahepatic portosystemic shunt (TIPS) or balloon-occluded retrograde transvenous obliteration (BRTO) (16) and endoscopic treatment; tissue adhesive injection; thrombin injection; sclerotherapy; or band ligation.

TIPS placement has been demonstrated to be useful in reducing rebleeding rates from GV despite that GV tend to bleed at lower portal pressures (11). However, TIPS seemed to be less effective for GV treatment than for esophageal varices (17). In another study, although TIPS insertion led to a successful reduction in the mean hepatoportal gradient (17 to 8.4 mm Hg), the actuarial rate of remaining free of rebleeding at 12 months was only 64%. Furthermore, TIPS was considered to be responsible for death in 13% of patients (18). In addition, TIPS is expensive and requires ongoing maintenance in the vast majority of patients.

Currently, among the endoscopic therapeutic options for gastric variceal bleeding, the greatest evidence for successful treatment exists for EVO using N-butyl-2-cyanoacrylate, which is recommended as a first-line endoscopic therapy (19-21). Uncontrolled data comparing therapies in bleeding fundal varices show that the best control of initial hemorrhage (90-100%) is achieved with EVO, TIPS, or BRTO (16). Three small single-center randomized, controlled trials compared EVO versus endoscopic sclerotherapy (22) or band ligation in bleeding GV (15, 23). All three trials are favorable for EVO regarding control of acute hemorrhage (15, 22), rebleeding (23), or complication rate (15). A small single-center study comparing EVO versus TIPS in the prevention of recurrent hemorrhage in patients in whom acute gastric variceal
hemorrhage was controlled with EVO showed similar rebleeding rates (24). Thus, it is possible that EVO would be as effective as TIPS, if not more so, particularly in patients with underlying encephalopathy, renal disease, or significantly decompensated liver disease.

Based on these data, all of the current guidelines, such as the American Society for Gastrointestinal Endoscopy guidelines, the American Association for the Study of Liver Diseases guidelines, and the Baveno IV Consensus, recommend EVO as first-line treatment for bleeding GV, with the option of TIPS where endoscopic therapy is not available (19-21).

Practical Considerations in EVO for Bleeding GV

Because EVO has the potential risk of serious complications, complying with standard injection technique is important to reduce the risks: 1) dilution of 0.5 mL N-butyl-2-cyanoacrylate with 0.5 mL or 0.8 mL of Lipiodol, 2) limiting the mixture volume to 1.0-1.3 mL per injection to minimize embolism risk, 3) repeating intravariceal injections of 1.0-1.3 mL each until hemostasis is achieved, 4) obliteration of all tributaries of the FV, 5) repeat endoscopy 1-4 days after the initial treatment to confirm complete obliteration of all visible varices and repeat EVO if necessary to accomplish complete obliteration (25).

Real-time fluoroscopy monitoring is not always necessary. An overtube should be kept readily available to easily remove and re-insert the endoscope during the procedure and also to prevent aspiration of gastric contents into the patient’s airway. A specialized catheter should be used, and distilled water is better than normal saline because cyanoacrylate may coagulate in contact with saline. Goggles are required for eye protection of the patient and the clinical personnel from splashes of cyanoacrylate during preparation and injection of the glue.

A routine check with dynamic CT scanning prior to EVO is strongly recommended (26-28). CT scanning is very helpful for identifying the presence and type of GV, to assess GV outflow direction, such as a gastro-renal shunt, to assess the risk of systemic embolization by EVO, to identify the presence of hepatocellular carcinoma with or without portal vein thrombosis, and to evaluate the applicability of salvage treatments, such as TIPS or BRTO, in cases of EVO failure.

In cases with active bleeding, securing the endoscopic view to the fundus is difficult due to the large amount of blood in the gastric lumen. In such cases, changing the position of the patient to an upright or prone position is sometimes dramatically helpful. In a case with a large fundal varix, the dome area of the varix has the highest pressure with a high speed of blood flow (Fig. 2). Thus, it is better to inject at the side of the varix first, moving the injection to the dome in a stepwise manner.

Potential Complications of EVO

Cyanoacrylate injection may cause some serious complications, including embolization into the renal vein, IVC, pulmonary or systemic vessels, fever, paravariceal injection with mucosal necrosis and bleeding, intraperitoneal injection inducing severe pain, needle sticking in the varix, and adherence of the glue to the endoscope. However, most of these complications can be prevented by keeping a standardized injection technique, and the overall incidence of complications is low (25, 29). Antibiotic prophylaxis should be administered to all cirrhotic patients with GI bleeding, whether EVO is performed or not.

Summary

Early endoscopic evaluation is essential for the diagnosis and treatment of variceal bleeding. EVO with cyanoacrylate...
Endoscopic Management of Bleeding Gastric Varices

glue injection is the recommendation of choice for acute GV bleeding, with the option of TIPS where endoscopic therapy is not available. By keeping a standardized technique, EVO can be performed safely and effectively.

REFERENCES

1. Navasa M, Parés A, Bruguera M, Caballería J, Bosch J, Rodés J. Portal hypertension in primary biliary cirrhosis. Relationship with histological features. J Hepatol 1987;5:292-298
2. Sanyal AJ, Fontana RJ, Di Biscaglie AM, Everhart JE, Doherty MC, Everson GT, et al. The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc 2006;64:855-864
3. Carbonell N, Pauwels A, Serfaty L, Fourdan O, Lévy VD, Poupon R. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology 2004;40:652-659
4. D’Amico G, De Franchis R; Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003;38:590-612
5. El-Serag HB, Everhart JE. Improved survival after variceal hemorrhage over an 11-year period in the Department of Veterans Affairs. Am J Gastroenterol 2000;95:3566-3573
6. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981;80:800-809
7. Sarin SK, Lahoti D, Saxena SP, Murthy NS, Makwana UK. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology 1992;16:1343-1349
8. Sarin SK. Long-term follow-up of gastric variceal sclerotherapy: an eleven-year experience. Gastrointest Endosc 1997;46:8-14
9. Arakawa M, Masuzaki T, Okuda K. Pathomorphology of esophageal and gastric varices. Semin Liver Dis 2002;22:73-82
10. Pollio J, Groszmann RJ. Hemodynamic factors involved in the development and rupture of esophageal varices: a pathophysiological approach to treatment. Semin Liver Dis 1986;6:318-331
11. Chao Y, Lin HC, Lee FY, Wang SS, Tsai YT, Hsia HC, et al. Hepatic hemodynamic features in patients with esophageal or gastric varices. J Hepatol 1993;19:85-89
12. North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med 1988;319:983-989
13. Burroughs AK. The management of bleeding due to portal hypertension. Part 1. The management of acute bleeding episodes. Q J Med 1988;67:447-458
14. Gostout CJ, Viggiano TR, Balm RK. Acute gastrointestinal bleeding from portal hypertensive gastropathy: prevalence and clinical features. Am J Gastroenterol 1993;88:2030-2033
15. Lo GH, Lai KH, Cheng JS, Chen MH, Chiang HT. A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology 2001;33:1060-1064
16. Ryan BM, Stockbrugger RW, Ryan JM. A pathophysiological, gastroenterological, and radiologic approach to the management of gastric varices. Gastroenterology 2004;126:1175-1189
17. Chau TN, Patch D, Chan YW, Nagral A, Dick R, Burroughs AK. “Salvage” transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology 1998;114:981-987
18. Barange K, Péron JM, Imani K, Otal P, Payen JL, Rousseau H, et al. Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices. Hepatology 1999;30:1139-1143
19. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922-938
20. Qureshi W, Adler DG, Davila R, Egan J, Hirota W, Leighton J, et al. ASGE Guideline: the role of endoscopy in the management of variceal hemorrhage, updated July 2005. Gastrointest Endosc 2005;62:651-655
21. de Franchis R; Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010;53:762-768
22. Sarin SK, Jain AK, Jain M, Gupta R. A randomized controlled trial of cyanoacrylate versus alcohol injection in patients with isolated fundic varices. Am J Gastroenterol 2002;97:1010-1015
23. Tan PC, Hou MC, Lin HC, Liu TT, Lee FY, Chang FY, et al. A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. Hepatology 2006;43:690-697
24. Lo GH, Liang HL, Chen WC, Chen MH, Lai KH, Hsu PI, et al. Transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy 2007;39:679-685
25. Seewald S, Ang TL, Imazu H, Naga M, Omar S, Groth S, et al. A standardized injection technique and regimen ensures safety and efficacy of N-butyl-2-cyanoacrylate injection for the treatment of gastric fundal varices (with videos). Gastrointest Endosc 2008;68:447-454
26. Willmann JK, Weishaupt D, Böhm T, Pfammatter T, Seifert B, Marineck B, et al. Detection of submucosal gastric fundal varices with multi-detector row CT angiography. Gut 2003;52:886-892
27. Matsumoto A, Kitamoto M, Inamura M, Nakanishi T, Ono C, Ito K, et al. Three-dimensional portography using multislice helical CT is clinically useful for management of gastric fundic varices. AJR Am J Roentgenol 2001;176:899-905
28. Rice JP, Lubner M, Taylor A, Spier BJ, Said A, Lucey MR, et al.
CT portography with gastric variceal volume measurements in the evaluation of endoscopic therapeutic efficacy of tissue adhesive injection into gastric varices: a pilot study. *Dig Dis Sci* 2011;56:2466-2472

29. Cheng LF, Wang ZQ, Li CZ, Lin W, Yeo AE, Jin B. Low incidence of complications from endoscopic gastric variceal obturation with butyl cyanoacrylate. *Clin Gastroenterol Hepatol* 2010;8:760-766